Hot Stocks: Brokerage view on Biocon, Info Edge, LIC Housing; Jefferies upgrades M&M

Hot Stocks: Brokerage view on Biocon, Info Edge, LIC Housing; Jefferies upgrades M&M

Brokerage firm JPMorgan maintained an overweight rating on LIC Housing Finance, Nomura has a buy rating on Info Edge, BofA Securities recommended a buy on Biocon and Jefferies upgraded M&M to buy. We have collated a list of recommendations from top brokerage firms from ETNow and other sources: JPMorgan on LIC Housing: Overweight| Target Rs … Read more

F&O stocks to buy today: SBI Life, Biocon among top 3 trading ideas for 1 March 2024

F&O stocks to buy today: SBI Life, Biocon among top 3 trading ideas for 1 March 2024

Indian market is expected to open higher on Friday tracking positive global cues. The Nifty future closed positive with gains of 0.28% at 21983 levels on Thursday. India VIX was down by 4.65% from 16.33 to 15.57 levels. Volatility cooled off after steaming in the entire week and paved the way for the bulls in … Read more

F&O stocks to buy today: 7 short-term trading ideas by experts for 8 January, 2024

F&O stocks to buy today: 7 short-term trading ideas by experts for 8 January, 2024

Indian benchmark indices ended Friday in the green, maintaining their two-session gaining streak on buying action in IT and auto stocks. The S&P BSE Sensex finished at 72,026, up by 178.58 points or 0.25%. Meanwhile, the broader Nifty settled at 21,710.80, higher by 52.20 points or 0.24%. India VIX, a measure of volatility in Nifty, … Read more

Tracking benchmarks? Please read broader market carefully

Tracking benchmarks? Please read broader market carefully

Mumbai: The benchmark Nifty has only corrected 2.5% in October so far, but granular data suggests bigger woes for investors. One such number, the advance-to-decline ratio for Nifty 500 stocks this month stands at 0.39, marking its lowest level in sixteen months, thereby underscoring the severity of the ongoing correction. This metric provides a deeper … Read more

Official action indicated for Biocon arm’s unit in Malaysia after USFDA inspection

Official action indicated for Biocon arm’s unit in Malaysia after USFDA inspection

Representational image only. | Photo Credit: The Hindu Biocon Limited on October 18 said the U.S. health regulator has classified as ‘official action indicated’ for the manufacturing facility of group firm Biocon Sdn Bhd at Johor, Malaysia following an inspection. The OAI (Official Action Indicated) status may cause delay and/or withholding of pending product approvals … Read more

Stocks to buy today: BHEL, ONGC among top 9 trading ideas for 13 July 2023

Stocks to buy today: BHEL, ONGC among top 9 trading ideas for 13 July 2023

Indian market is likely to consolidate on Thursday tracking muted global cues. The S&P BSE Sensex fell more than 200 points while the Nifty50 closed below 19400 levels in the previous trading session. India VIX was down by 0.68% from 11.01 to 10.93 levels on Wednesday. Volatility sunk lower and is hovering near its lower … Read more

Stock screener: MFs, FIIs drool over these 10 stocks, earn double-digit returns

Stock screener: MFs, FIIs drool over these 10 stocks, earn double-digit returns

In the last three quarters, both FIIs and mutual funds have hiked stakes in at least 20 stocks but only 10 of them have rewarded the big boys of Dalal Street with double-digit returns so far in FY24. Topping the list of stocks with rising institutional ownership in FY23 is L&T Finance Holdings which has … Read more

Biocon shares jump 8% post Q4 results. Is the Street happy?

Biocon shares jump 8% post Q4 results. Is the Street happy?

Shares of Biocon surged 8% in intraday trade on Tuesday after the company reported strong earnings growth for the three months ended March period. The stock hit a high of Rs 260 and is currently trading 2.5% higher at Rs 247.5 apiece on NSE. The pharmaceutical major’s net profit rose 31% to Rs 313 crore … Read more

Biocon Q4 Results: Cons PAT grows 31% YoY to Rs 313 crore, revenue surges 57%

Biocon Q4 Results: Cons PAT grows 31% YoY to Rs 313 crore, revenue surges  57%

MUMBAI – Pharmaceutical major Biocon today reported a 31.3% year-on-year (YoY) rise in consolidated net profit for the March quarter to Rs 313 crore on the back of a strong revenue growth. Consolidated revenue from operations increased 57% on year to Rs 3,774 crore. The board has recommended a final dividend payout of Rs 1.50 … Read more

2 top stock recommendations from Swati Ananda Hotkar

2 top stock recommendations from Swati Ananda Hotkar

“Any move above 18,200, again we will retest the 18,400, 18,600 levels. So, the view is not major negative as of now. I believe market is giving an opportunity to take a buy call on every dip as long as 17,900 level is well placed,” says Swati Ananda Hotkar, Nirmal Bang SecuritiesWhat is your take … Read more